Document:

EX-10.1

 Exhibit 10.1 

Form of CVR Agreement 

CONTINGENT VALUE RIGHTS AGREEMENT 

THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [—], 2014
(this “Agreement”), is entered into by and between Forest Laboratories, Inc., a Delaware corporation (“Parent”), and [—], a [—], as Rights Agent. 
 RECITALS 

A. Parent, Royal Empress, Inc., a Delaware corporation (“Merger Sub”), and Furiex Pharmaceuticals, Inc., a Delaware
corporation (the “Company”), have entered into an Agreement and Plan of Merger, dated as of April 27, 2014 (as amended from time to time, the “Merger Agreement”), pursuant to which Merger Sub will merge with
and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. 
 B. Pursuant to the Merger Agreement, and
in accordance with the terms and conditions thereof, Parent has agreed to provide to the Holders (as defined below) the right to receive a contingent payment upon the achievement of one of certain milestones as hereinafter described. 

AGREEMENT 
 The parties to this
Agreement, for and in consideration of the premises and the consummation of the transactions referred to above, intending to be legally bound, hereby mutually covenant and agree, for the equal and proportionate benefit of all Holders (as defined
below), as follows: 
 SECTION 1 DEFINITIONS 

1.1 Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger
Agreement. The following terms shall have the meanings ascribed to them below: 
 “Acting Holders” means, at the time of
determination, any Holder or Holders of at least a majority of the outstanding CVRs as set forth on the CVR Register. 
 “Board of
Directors” means the board of directors of Parent. 
 “Board Resolution” means a copy of a resolution
(a) certified by a duly authorized officer of Parent to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification and (b) delivered to the Rights Agent. 

“Business Day” means any day except a Saturday, Sunday or other day on which the SEC or banks in the City of New York are
authorized or required by Law to be closed. 

 “Carve-Out Transaction” means any transaction (including a sale of assets,
merger, sale of stock or other equity interests, or exclusive licensing transaction), other than a Change of Control, pursuant to which a substantial portion of the Intellectual Property (including without limitation, any data, marketing
authorizations and applications for marketing authorization) and/or Company Material Contracts held or owned by the Surviving Corporation immediately after the Effective Time and necessary for the production, development and sale of the Product are
sold or exclusively licensed (directly or indirectly, including through sale of or exclusive license by any Subsidiary of the Surviving Corporation) to or acquired by, directly or indirectly, a Person other than Parent or any of its Subsidiaries.

 “Change of Control” means (a) a sale or other disposition of all or substantially all of the assets of either of
Parent on a consolidated basis (other than to any Subsidiary (direct or indirect) of Parent), (b) a merger or consolidation involving Parent in which Parent is not the surviving entity, and (c) any other transaction involving Parent in
which Parent is the surviving entity but in which the stockholders of Parent immediately prior to such transaction own less than fifty percent (50%) of Parent’s voting power immediately after the transaction. 

“CSA” means the U.S. Controlled Substances Act, as amended. 

“CVRs” means the rights of Holders to receive a contingent cash payment pursuant to the Merger Agreement and this Agreement.

 “CVR Register” has the meaning set forth in Section 2.3(b). 

“DEA” means the U.S. Drug Enforcement Administration in the U.S. Department of Justice, or any successor agency. 

“Eluxadoline” means the compound having the chemical name
5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid, commonly referred to as “eluxadoline”. 

“FDA” means the U.S. Food and Drug Administration, or any successor agency. 

“Holder” means, at the relevant time, a Person in whose name a CVR is registered in the CVR Register. 

“Loss” has the meaning set forth in Section 3.2(g). 

“Milestone” means each of (a) a Schedule IV Event, (b) a Schedule V Event, and (c) a Non-Schedule Event. 

“Milestone Payment” means, as applicable, (a) the Schedule IV Event Payment (in the case of a Schedule IV Event),
(b) the Schedule V Event Payment (in the case of a Schedule V Event), and (c) the Non-Schedule Event Payment (in the case of a Non-Schedule Event). 

“Milestone Payment Date” has the meaning set forth in Section 2.4(a). 

“Milestone Satisfaction Notice” has the meaning set forth in Section 2.4(a). 

  
 2 

 “NDA Approval” means the first approval by the FDA of a New Drug Application for
the Product. 
 “Non-Schedule Event” means the occurrence of all of the following: (a) NDA Approval; (b) the FDA
having not recommended in connection with such NDA Approval that Eluxadoline be a controlled substance under any Schedule of the CSA; and (c) during the six-month period following such NDA Approval, the DEA not having proposed (or announced the
intention to propose) any rule providing for the control of Eluxadoline in any schedule of the CSA. 
 “Non-Schedule Event
Payment” means an amount equal to $30.00 per CVR, payable in cash in United States Dollars. 
 “Officer’s
Certificate” means a certificate (a) signed by the President, a Vice President, the Treasurer or the Secretary of Parent, in his or her capacity as such officer, and (b) delivered to the Rights Agent. 

“Permitted Transfer” means a transfer of one or more CVRs (a) upon death by will or intestacy; (b) by instrument to
an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c) made pursuant to a court order; (d) made by operation of law (including a consolidation or merger) or without
consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (e) in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if
applicable, through an intermediary) or from such nominee to another nominee for the same beneficial owner, in each case as allowable by The Depository Trust Company; or (f) as provided in Section 2.6. 

“Person” means any individual, estate, corporation, limited liability company, partnership, association, trust,
unincorporated organization, joint venture or other entity or group (as defined in the Exchange Act), and shall include any successor (by merger or otherwise) thereof or thereto. 

“Product” means the product that includes Eluxadoline as the sole active pharmaceutical ingredient that is currently being
developed by the Company. 
 “Rights Agent” means the Rights Agent named in the first paragraph of this Agreement, until a
successor Rights Agent shall have become such pursuant to the applicable provisions of this Agreement, and thereafter “Rights Agent” shall mean such successor Rights Agent. 

“Schedule IV Event” means the occurrence of all of the following: (a) NDA Approval; (b) the first publication in
the U.S. Federal Register of a final rule of the DEA that amends Title 21 of the Code of Federal Regulations part 1308 to designate Eluxadoline as a controlled substance under any Schedule of the CSA; and (c) the final rule described in clause
(b) providing for Eluxadoline to be a controlled substance under Schedule IV of the CSA. 
 “Schedule IV Event
Payment” means an amount equal to $10.00 per CVR, payable in cash in United States Dollars. 

  
 3 

 “Schedule V Event” means the occurrence of all of the following: (a) NDA
Approval; (b) the first publication in the U.S. Federal Register of a final rule of the DEA that amends Title 21 of the Code of Federal Regulations part 1308 to designate Eluxadoline as a controlled substance under any Schedule of the CSA; and
(c) the final rule described in clause (b) providing for Eluxadoline to be a controlled substance under Schedule V of the CSA. 

“Schedule V Event Payment” means an amount equal to $20.00 per CVR, payable in cash in United States Dollars. 

“Termination Event” means either: (a) the failure to achieve NDA Approval on or prior to the second anniversary of the
date hereof; or (b) the publication in the U.S. Federal Register of a final rule of the DEA that amends Title 21 of the Code of Federal Regulations part 1308 to designate Eluxadoline as a controlled substance under any of Schedule I, Schedule
II or Schedule III of the CSA. 
 SECTION 2 CONTINGENT VALUE RIGHTS 

2.1 CVRs; Appointment of Rights Agent. 

(a) As provided in the Merger Agreement, each Holder shall be entitled to one CVR for each share of Company Common Stock outstanding or
underlying each Option and share of Restricted Stock that is owned by or has been issued to such Holder as of immediately prior to the Effective Time and is converted into the right to receive the Merger Consideration pursuant to the Merger
Agreement. 
 (b) Parent hereby appoints the Rights Agent to act as rights agent for Parent in accordance with the terms and
conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. 
 2.2 Nontransferable. The CVRs shall
not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than pursuant to a Permitted Transfer. 

2.3 No Certificate; Registration; Registration of Transfer; Change of Address. 

(a) The CVRs shall not be evidenced by a certificate or other instrument. 

(b) The Rights Agent shall keep a register (the “CVR Register”) for the purposes of (i) identifying the Holders
of CVRs and (ii) registering CVRs and Permitted Transfers thereof. 
 (c) Subject to the restrictions on transferability set
forth in Section 2.2, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer and other requested documentation in form reasonably satisfactory to the Rights Agent, duly executed by the Holder
or Holders thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the
Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form and the 

  
 4 

 
transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of Section 2.2), register the transfer of the applicable CVRs in the CVR Register.
All duly transferred CVRs registered in the CVR Register shall be the valid obligations of Parent, evidencing the same right, and shall entitle the transferee to the same benefits and rights under this Agreement, as those held by the transferor. No
transfer of a CVR shall be valid until registered in the CVR Register, and any transfer not duly registered in the CVR Register will be void ab initio. Any transfer or assignment of the CVRs shall be without charge (other than the cost of any
transfer tax) to the applicable Holder. 
 (d) A Holder may make a written request to the Rights Agent to change such Holder’s
address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register. 

2.4 Payment Procedures. 

(a) If a Milestone occurs, then on a date (the “Milestone Payment Date”) that is within 10 Business Days following
such event, Parent shall deliver to the Rights Agent (i) a notice (the “Milestone Satisfaction Notice”) which shall be in the form of an Officer’s Certificate stating the date of the satisfaction of such Milestone and that
the Holders are entitled to receive the applicable Milestone Payment and (ii) cash in the aggregate amount of the Milestone Payment payable to the Holders. In no event shall payment be made with respect to more than a single Milestone. 

(b) The Rights Agent shall promptly, and in no event later than 10 Business Days after receipt, (i) send each Holder at its
address set forth in the CVR Register a copy of the Milestone Satisfaction Notice and (ii) pay the Milestone Payment to each of the Holders (the amount which each Holder is entitled to receive, subject to Section 2.4(c), will be based on
the applicable Milestone Payment multiplied by the number of CVRs held by such Holder at the time of such payment as reflected on the CVR Register) by check mailed to the address of each Holder as set forth in the CVR Register as of the close of
business on the first Business Day prior to the Milestone Payment Date. 
 (c) Except to the extent any portion of the Milestone
Payment is required to be treated as imputed interest pursuant to applicable Law, the Holders and the parties hereto agree to treat the CVRs and the Milestone Payment for all Tax purposes as additional consideration for the shares of Common Stock,
Options and shares of Restricted Stock pursuant to the Merger Agreement, and none of the Holders and the parties hereto will take any position to the contrary on any Tax Return or for other Tax purposes except as required by applicable Law. Parent
and the Company shall report imputed interest on the CVRs pursuant to Section 483 of the Code. 
 (d) Parent shall be entitled
to deduct and withhold, or cause to be deducted and withheld, from the Milestone Payment otherwise payable pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under any
provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld and paid over to or deposited with the relevant Governmental Authority, 

  
 5 

 
such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Holder in respect of which such deduction and withholding was made. Prior to making any such
tax withholdings or causing any such tax withholdings to be made with respect to any Holder, the Rights Agent shall, to the extent practicable, provide notice to the Holder of such potential withholding and a reasonable opportunity for the Holder to
provide any necessary tax forms (including an IRS Form W-9 or an applicable IRS Form W-8) in order to avoid or reduce such withholding amounts; provided that the time period for payment of a Milestone Payment by the Rights Agent set forth in
Section 2.4(b) shall be extended by a period equal to any delay caused by the Holder providing such forms. 
 (e) Any portion of
the Milestone Payment that remains undistributed to the Holders for six months after the Milestone Payment Date shall be delivered by the Rights Agent to Parent, upon demand, and any Holder shall thereafter look only to Parent for payment of such
Milestone Payment, but shall have no greater rights against Parent than may be accorded to general unsecured creditors of Parent under applicable Law. 

(f) Neither Parent nor the Rights Agent shall be liable to any Person in respect of a Milestone Payment delivered to a public official
pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law. If the Milestone Payment (or portion thereof) made by Parent remains unclaimed by a Holder two years after the applicable Milestone Payment
Date (or immediately prior to such earlier date on which the Milestone Payment would otherwise escheat to or become the property of any Governmental Authority), any such Milestone Payment (or portion thereof) shall, to the extent permitted by
applicable Law, become the property of Parent, free and clear of all claims or interest of any Person previously entitled thereto. 
 2.5
No Voting, Dividends or Interest; No Equity or Ownership Interest in Parent. 
 (a) The CVRs shall not have any voting or
dividend rights, and interest shall not accrue on any amounts payable in respect of the CVRs. 
 (b) The CVRs shall not represent any
equity or ownership interest in Parent, in any constituent company to the Merger or any of their respective Affiliates. 
 2.6 Ability To
Abandon The CVR. The Holder of a CVR may at any time, at such Holder’s option, abandon all of such Holder’s remaining rights in a CVR by transferring such CVR to Parent without consideration therefor. Nothing in this Agreement is
intended to prohibit Parent from offering to acquire CVRs for consideration in its sole discretion. 
 SECTION 3 THE RIGHTS AGENT 

3.1 Certain Duties And Responsibilities. 

(a) The Rights Agent shall not have any liability for any actions taken or not taken in connection with this Agreement, except to the
extent of its willful misconduct, bad faith or gross negligence. 

  
 6 

 (b) The Acting Holders may direct the Rights Agent to act on behalf of the Holders in
enforcing any of their rights hereunder. The Rights Agent shall be under no obligation to institute any action, suit or proceeding, or to take any other action likely to result in the incurrence of material expenses by the Rights Agent, unless the
Acting Holders (on behalf of the Holders) shall furnish the Rights Agent with reasonable security and indemnity for any costs and expenses that may be incurred. All rights of action under this Agreement may be enforced by the Rights Agent, any
action, suit or proceeding instituted by the Rights Agent shall be brought in its name as the Rights Agent and any recovery in connection therewith shall be for the proportionate benefit of all the Holders, as their respective rights or interests
may appear. 
 3.2 Certain Rights of Rights Agent. 

(a) The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no
implied covenants or obligations shall be read into this Agreement against the Rights Agent. 
 (b) The Rights Agent may rely and
shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in good faith to be genuine and to
have been signed or presented by the proper party or parties. 
 (c) Whenever the Rights Agent shall deem it desirable that a matter
be proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may, in the absence of bad faith, gross negligence or willful misconduct on its part, rely upon an Officer’s Certificate. 

(d) The Rights Agent may engage and consult with counsel of its selection and the written advice or opinion of such counsel shall be
full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon. 

(e) Any permissive rights of the Rights Agent hereunder shall not be construed as a duty. 

(f) The Rights Agent shall not be required to give any note or surety in respect of the execution of such powers or otherwise in
respect of the premises. 
 (g) Parent agrees to indemnify Rights Agent for, and hold Rights Agent harmless from and against, any
loss, liability, damage or expense (“Loss”) suffered or incurred by the Rights Agent and arising out of or in connection with Rights Agent’s performance of its obligations under this Agreement, including the reasonable costs
and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection with such performance, except to the extent such Loss shall have been determined by a court of competent jurisdiction
to have result from the Rights Agent’s gross negligence, bad faith or willful misconduct. Parent’s obligations under this Section 3.2(g) to indemnify the Rights Agent shall survive the resignation or removal of any Rights Agent and
the termination of this Agreement. 

  
 7 

 (h) In addition to the indemnification provided under Section 3.2(g), Parent agrees
(i) to pay the fees and expenses of the Rights Agent in connection with the Rights Agent’s performance of its obligations hereunder, as agreed upon in writing by Rights Agent and Parent on or prior to the date of this Agreement, and
(ii) to reimburse the Rights Agent promptly upon demand for all reasonable and documented out-of-pocket expenses, including all Taxes (other than income, receipt, franchise or similar Taxes) and governmental charges, incurred by the Rights
Agent in the performance of its obligations under this Agreement. 
 3.3 Resignation and Removal; Appointment of Successor. 

(a) The Rights Agent may resign at any time by giving written notice thereof to Parent and the Holders specifying a date when such
resignation shall take effect, which notice shall be sent at least 60 days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). 

(b) Parent shall have the right to remove the Rights Agent at any time by a Board Resolution specifying a date when such removal shall
take effect. Notice of such removal shall be given by Parent to Rights Agent, which notice shall be sent at least 60 days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). 

(c) If the Rights Agent shall resign, be removed or become incapable of acting, Parent shall promptly appoint a qualified successor
Rights Agent by a Board Resolution. The successor Rights Agent so appointed shall, forthwith upon its acceptance of such appointment in accordance with this Section 3.3(c) and Section 3.4, become the successor Rights Agent for all purposes
hereunder. 
 (d) Any Person into which the Rights Agent may be merged or with which it may be consolidated, or any Person resulting
from any merger, conversion or consolidation to which the Rights Agent shall be a party, or any Person succeeding to the corporate trust or stockholder services business of the Rights Agent, shall be the successor to the Rights Agent under this
Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto. 
 (e) Parent
shall give notice of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent by mailing written notice of such event by first-class mail, postage prepaid, to the Holders as their names and addresses appear in
the CVR Register. Each notice shall include the name and address of the successor Rights Agent. If Parent fails to send such notice within 10 Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent shall
cause the notice to be mailed at the expense of Parent. 
 (f) Notwithstanding anything to the contrary in this Section 3.3,
unless consented to in writing by the Acting Holders, Parent shall not appoint as a successor Rights Agent any Person that is not a stock transfer agent or the corporate trust department of a commercial bank, in either case of national reputation.

 3.4 Acceptance of Appointment By Successor. Every successor Rights Agent appointed hereunder shall, at or prior to such
appointment, execute, acknowledge and deliver to 

  
 8 

 
Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or
conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Rights Agent; provided that upon the request of Parent or the successor Rights Agent, such resigning or removed Rights Agent shall execute and
deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. 
 SECTION
4 COVENANTS 
 4.1 List of Holders. Parent shall furnish or cause to be furnished to the Rights Agent, in such form as Parent
receives from the Company’s transfer agent (or other agent performing similar services for the Company), the names and addresses of the Holders within 30 Business Days of the Closing Date. 

4.2 Payment of the Milestone Payment. Parent shall duly and promptly deposit with the Rights Agent for payment to the Holders the
Milestone Payment, if any, in the manner provided for in Section 2.4 and in accordance with the terms of this Agreement. 
 4.3
Fundamental Transactions. In the event that Parent desires to consummate a Change of Control or Carve-Out Transaction after the Effective Date while any Milestone has not been attained but remains eligible to be attained, Parent or the Surviving
Corporation, as applicable depending upon the structure of the Change of Control or Carve-Out Transaction, shall cause the Person acquiring Parent (or acquiring substantially all of its assets or otherwise exclusively licensing rights to
Eluxadoline) with respect to a Change of Control or the Person acquiring the subject Intellectual Property rights, Company Material Contracts and/or Subsidiaries with respect to a Carve-Out Transaction to assume Parent’s and the Surviving
Corporation’s (as applicable depending upon the structure of the Change of Control or Carve-Out Transaction) obligations, duties and covenants under this Agreement. No later than five Business Days prior to the consummation of any Change of
Control or Carve-Out Transaction, Parent shall deliver to the Rights Agent an Officer’s Certificate, stating that such Change of Control or Carve-Out Transaction complies with this Section 4.3 and that all conditions precedent herein
provided for relating to such transaction have been complied with. 
 SECTION 5 AMENDMENTS 

5.1 Amendments Without Consent of Holders or Rights Agent. 

(a) Parent, when authorized by a Board Resolution, at any time and from time to time, may unilaterally enter into one or more
amendments hereto, for any of the following purposes, without the consent of any of the Holders or the Rights Agent, so long as, in the cases of clauses (ii) through (iv), such amendments do not adversely affect the interests of the Holders:

 (i) to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of
the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; 

  
 9 

 (ii) to add to the covenants of Parent such further covenants, restrictions, conditions
or provisions as the Board of Directors shall determine to be for the protection of the Holders; 
 (iii) to cure any ambiguity, to
correct or supplement any provision herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; 

(iv) as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the
Exchange Act; or 
 (v) any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this
Agreement, unless such addition, elimination or change is materially adverse to the interests of the Holders. 
 (b) Promptly after
the execution by Parent of any amendment pursuant to the provisions of this Section 5.1, Parent shall mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the Holders at their addresses as they shall appear on the
CVR Register, setting forth in general terms the substance of such amendment. 
 5.2 Amendments With Consent of Holders. 

(a) In addition to any amendments to this Agreement that may be made by Parent without the consent of any Holder or the Rights Agent
pursuant to Section 5.1, with the consent of the Acting Holders, whether evidenced in writing or taken at a meeting of the Holders, Parent, when authorized by a Board Resolution, and the Rights Agent may enter into one or more amendments hereto
for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is adverse to the interests of the Holders. 

(b) Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this Section 5.2,
Parent shall mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the Holders at their addresses as they shall appear on the CVR Register, setting forth in general terms the substance of such amendment. 

5.3 Execution of Amendments. In executing any amendment permitted by this Article V, the Rights Agent shall be entitled to receive, and
shall be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized or permitted by this Agreement. The Rights Agent may, but is not obligated to, enter into any such
amendment that affects the Rights Agent’s own rights, privileges, covenants or duties under this Agreement or otherwise. 
 5.4
Effect of Amendments. Upon the execution of any amendment under this Article V, this Agreement shall be modified in accordance therewith, such amendment shall form a part of this Agreement for all purposes and every Holder shall be bound
thereby. 

  
 10 

 SECTION 6 MISCELLANEOUS PROVISIONS 

6.1 Entire Agreement; Counterparts. This Agreement and the Merger Agreement constitute the entire agreement, and supersede all other
prior agreements and understandings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof and thereof. This Agreement may be executed in counterparts (each of which shall be deemed to be an original but
all of which taken together shall constitute one and the same agreement) and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by electronic communication, facsimile or otherwise) to the
other parties. Until and unless each party has received a counterpart hereof signed by the other parties hereto, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or
written agreement or other communication). 
 6.2 Notices To Rights Agent and Parent. All notices, requests and other communications
to any party hereunder shall be in writing and shall be deemed given if delivered personally, facsimiled (which is confirmed) or sent by overnight courier (providing proof of delivery) to the parties at the following addresses: 

 

			
	if to Parent, to:
	
	Forest Laboratories, Inc.
	909 Third Avenue
	New York, NY 10022
	Attention:	  	A. Robert D. Bailey, General Counsel
	Facsimile:	  	(212) 224-6740
	
	with a copy (which shall not constitute notice) to:
	
	Covington & Burling LLP
	The New York Times Building
	620 Eighth Avenue
	New York, NY 10018
	Attention:	  	Andrew W. Ment
	Facsimile:	  	(646) 441-9012
	
	if to the Rights Agent:
		
	[—]	  	
	[—]	  	
	Attention:	  	[—]
	Facsimile:	  	[—]
	
	with a copy (which shall not constitute notice) to:
		
	[—]	  	
	[—]	  	
	Attention:	  	[—]
	Facsimile:	  	[—]

  
 11 

 6.3 Notice To Holders. Where this Agreement provides for notice to Holders, such notice
shall be sufficiently given (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at his, her or its address as it appears in the CVR Register, not later than the
latest date, and not earlier than the earliest date, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular
Holder shall affect the sufficiency of such notice with respect to other Holders. 
 6.4 Successors and Assigns; Assignability. This
Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Holders and the parties hereto and their respective successors and assigns. The Rights Agent may not assign this Agreement without Parent’s
prior written consent. Except in connection with a Carve-Out Transaction or a Change of Control, Parent may not assign this Agreement without the prior written consent of the Acting Holders. Any attempted assignment of this Agreement or any of such
rights in violation of this Section 6.4 shall be void and of no effect. 
 6.5 Benefits of Agreement. Nothing in this Agreement,
express or implied, shall give to any Person (other than the parties hereto, the Holders and their permitted successors and assigns hereunder) any rights, remedies, benefits, obligations, liabilities or claims under this Agreement or under any
covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the parties hereto, the Holders and their permitted successors and assigns. The Holders shall have no rights hereunder except as are expressly
set forth herein and in the Merger Agreement. 
 6.6 Governing Law; Jurisdiction. 

(a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to
any choice or conflict of laws provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. 

(b) Each of the parties hereto hereby agrees that (i) all actions and proceedings arising out of or relating to this Agreement
shall be heard and determined in the Chancery Court of the State of Delaware and any state appellate court therefrom sitting in New Castle County in the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept
jurisdiction over a particular matter, any state or federal court within the State of Delaware), (ii) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, and
(iii) a final Judgment in any action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the Judgment or in any other manner provided by Law. 

(c) Each party irrevocably consents to the service of process outside the territorial jurisdiction of the courts referred to in this
Section 6.6 in any such action or proceeding by mailing copies thereof by registered or certified United States mail, postage 

  
 12 

 
prepaid, return receipt requested, to its address as specified in or pursuant to this Agreement. However, the foregoing shall not limit the right of a party to effect service of process on the
other party by any other legally available method. 
 6.7 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND
ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES HERETO ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 6.8 Legal
Holidays. In the event that a Milestone Payment Date shall not be a Business Day, then, notwithstanding any provision of this Agreement to the contrary, any payment required to be made in respect of the CVRs on such date need not be made on such
date, but may be made on the next succeeding Business Day with the same force and effect as if made on the applicable Milestone Payment Date. 

6.9 Severability. If any term or other provision of this Agreement is determined by a court of competent jurisdiction or other
Governmental Authority to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms, provisions and conditions of this Agreement shall nevertheless remain in full force and effect. Upon such
determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible to
the fullest extent permitted by applicable law in a mutually acceptable manner to the end that the transactions contemplated by this Agreement are fulfilled to the extent possible. 

6.10 Termination. This Agreement shall be terminated and of no force or effect, the parties hereto shall have no liability hereunder,
and no payments shall be required to be made, upon the earlier to occur of (a) the payment of the Milestone Payment required to be paid under the terms of this Agreement and (b) a Termination Event. The termination of this Agreement shall
not affect or limit the right to receive the Milestone Payment under Section 2.4 to the extent earned prior to termination of this Agreement and the provisions applicable thereto shall survive the expiration or termination of this Agreement.

 6.11 Enforcement of Agreement. In the event that a Holder is required to take any action to enforce such Holder’s rights
hereunder, such Holder, in addition to all other rights and remedies available hereunder, shall have the right to recover from Parent all out-of-pocket costs and expenses (including attorneys’ fees) incurred in connection therewith. 

6.12 Construction. When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement
unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” or
“including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and “hereunder” and words of similar import when used in
this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine
as well as to the feminine 

  
 13 

 
and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement, instrument
or statute as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and references to all
attachments thereto and instruments incorporated therein and the rules and regulations promulgated thereunder. References to a Person are also to its permitted assigns and successors. 

6.13 No Obligation. Notwithstanding anything in this Agreement to the contrary, in no event shall Parent or any of its Affiliates, be
required to undertake any level of efforts, or employ any level of resources, to develop, market, or commercialize Eluxadoline or any product containing Eluxadoline. 

[Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by
its duly authorized officers as of the day and year first above written. 
  

			
	FOREST LABORATORIES, INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	[RIGHTS AGENT]
		
	By:	 	  

		 	Name:
		 	Title:EX-10.2

 Exhibit 10.2 

STOCKHOLDER VOTING AGREEMENT 

THIS STOCKHOLDER VOTING AGREEMENT, dated as of April 27, 2014 (this “Agreement”), is entered into by and
between Forest Laboratories, Inc., a Delaware corporation (“Parent”), and each of the individuals or entities listed on the signature pages hereto (each, a “Stockholder” and, together, the
“Stockholders”). 
 RECITALS 

A. Concurrently with the execution and delivery of this Agreement, Parent, Royal Empress, Inc., a Delaware corporation (“Merger
Sub”), and Furiex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are entering into that certain Agreement and Plan of Merger, dated as of the date hereof (as amended from time to time, the “Merger
Agreement”; capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly
owned subsidiary of Parent. 
 B. As a condition and inducement to the willingness of Parent and Merger Sub to enter into the Merger
Agreement, each of Parent and Merger Sub has required that the Stockholders agree, and the Stockholders have agreed, to enter into this Agreement with respect to all shares of Company Common Stock that each Stockholder beneficially owns (for
purposes of this Agreement, as defined in Rule 13d-3 under the Exchange Act) as of the date hereof, as set forth on the signature page hereto (the “Subject Shares”). 

AGREEMENT 
 The parties to
this Agreement, for and in consideration of the premises and the consummation of the transactions referred to above, intending to be legally bound, hereby mutually covenant and agree as follows: 

SECTION 1 VOTING AGREEMENT; GRANT OF PROXY 

1.1 Voting Agreement. 

(a) During the Agreement Period (as defined below), each Stockholder hereby agrees that, at any meeting (whether annual or special and
whether or not an adjourned or postponed meeting) of the holders of shares of Company Common Stock, however called (each, a “Company Stockholders Meeting”), and in connection with any written consent of the holders of shares of
Company Common Stock, such Stockholder shall, unless Parent votes the Subject Shares pursuant to the proxy granted by Section 1.2 below, vote (or cause to be voted) or, if applicable, deliver (or cause to be delivered) a written consent with
respect to all of such Stockholder’s Subject Shares, in each case, to the fullest extent that such Subject Shares are entitled to be voted at the time of any vote or action by written consent: 

(i) in favor of (A) the adoption of the Merger Agreement, the Merger and all agreements related to the Merger and any actions
related thereto; and (B) without limitation of the preceding clause (A), the approval of any proposal to adjourn or postpone the Company Stockholders Meeting to a later date if there are not sufficient votes for adoption of the Merger Agreement
on the date on which the Company Stockholders Meeting is held; and 

 (ii) against (A) any Acquisition Proposal or any Alternative Acquisition Agreement;
(B) any election of new directors to the Company Board, other than nominees to the Company Board who are serving as directors of the Company on the date hereof who are nominated for election by a majority of the Company Board, or as otherwise
provided in the Merger Agreement; (C) any action, proposal, transaction or agreement that would reasonably be expected to result in a breach of any covenant, representation or warranty or any other obligation or agreement of such Stockholder
under this Agreement or of the Company under the Merger Agreement; (D) except as required pursuant to Section 1.1(a)(i), (I) any extraordinary corporate transaction, such as a merger, consolidation, sale of substantially all of the
assets of the Company or other business combination involving the Company and (II) any reorganization, recapitalization, dissolution, liquidation or winding up of the Company; and (E) any corporate action the consummation of which would
frustrate the purposes, or prevent or delay the consummation, of the Transactions. 
 (b) Subject to the proxy granted under
Section 1.2 below, each Stockholder shall retain at all times the right to vote or exercise such Stockholder’s right to consent with respect to such Stockholder’s Subject Shares in such Stockholder’s sole discretion and without
any other limitation on those matters other than those set forth in Section 1.1(a) that are at any time or from time to time presented for consideration to the Company’s stockholders generally; provided that such vote or consent
would not reasonably be expected to frustrate the purposes, or prevent or delay consummation, of the Transactions. 
 1.2 Irrevocable
Proxy. 
 (a) Each Stockholder hereby revokes (or agrees to cause to be revoked) any and all proxies that it has heretofore
granted with respect to the Subject Shares, other than the proxy for the Company’s annual meeting to be held May 22, 2014 with respect to the matters set forth in the proxy materials therefor filed with the SEC on April 11, 2014. Each
Stockholder hereby irrevocably appoints Parent as attorney-in-fact and proxy, with full power of substitution, for and on behalf of such Stockholder, for and in the name, place and stead of such Stockholder, to (i) vote, express consent or
dissent or issue instructions to the record holder of such Stockholder’s Subject Shares to vote such Subject Shares in accordance with the provisions of Section 1.1 at any Company Stockholders Meeting, and (ii) grant or withhold, or
issue instructions to the record holder of such Stockholder’s Subject Shares to grant or withhold, in accordance with the provisions of Section 1.1, all written consents with respect to the Subject Shares. 

(b) The foregoing proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be
affected by the death, incapacity, mental illness or insanity of such Stockholder) until the end of the Agreement Period and shall not be terminated by operation of any Law or upon the occurrence of any other event other than the termination of this
Agreement pursuant to Section 4.3 (and shall be terminated and revoked upon such termination). Each Stockholder hereby affirms that the irrevocable proxy set forth in this Section 1.2 is given in connection with, and granted in
consideration of and as an 

  
 2 

 
inducement to Parent entering into the Merger Agreement and that such irrevocable proxy is given to secure the obligations of such Stockholder under Section 1.1. Parent covenants and agrees
with each Stockholder that Parent will exercise the foregoing proxy consistent with the provisions of Section 1.1. 
 SECTION 2 REPRESENTATIONS AND
WARRANTIES 
 2.1 Representations and Warranties of Stockholder. Each Stockholder, severally but not jointly as to any other
Stockholder, represents and warrants to Parent as follows as of the date hereof: 
 (a) Organization. If such Stockholder is
not an individual, it is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization. 

(b) Authorization. If such Stockholder is not an individual, it has the requisite corporate, limited liability company,
partnership or trust power and authority, and has taken all action necessary, to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. If such Stockholder is an individual, such
Stockholder has full legal capacity, right and authority to execute and deliver this Agreement and to perform such Stockholder’s obligations hereunder. This Agreement has been duly executed and delivered by such Stockholder and constitutes a
legal, valid and binding obligation of such Stockholder and, assuming the due authorization, execution and delivery hereof by Parent, is enforceable against such Stockholder in accordance with its terms, subject to the Bankruptcy and Equity
Exception. If such Stockholder is married, and any of the Subject Shares of such Stockholder constitute community property or otherwise need spousal or other approval for this Agreement to be legal, valid and binding, this Agreement has been duly
executed and delivered by such Stockholder’s spouse and, assuming the due authorization, execution and delivery hereof by Parent, is enforceable against such Stockholder’s spouse in accordance with its terms, subject to the Bankruptcy and
Equity Exception. If this Agreement is being executed in a representative or fiduciary capacity, the Person signing this Agreement has full power and authority to enter into and perform this Agreement. 

(c) No Conflict. 

(i) Neither the execution and delivery of this Agreement by such Stockholder nor the consummation by such Stockholder of the
transactions contemplated hereby, nor compliance by such Stockholder with any of the terms or provisions hereof, will (A) if such Stockholder is not an individual, conflict with or violate any provision of its articles of incorporation, bylaws
or similar organizational documents, (B) assuming that each of the filings referred to in Section 2.1(c)(ii) are made and any applicable waiting periods referred to therein have expired, violate any Law or Judgment applicable to such
Stockholder, or (C) require any consent or other action by any Person under, result in any violation or breach of, result in the loss of a benefit under, conflict with any provision of, or constitute a default (with or without notice or lapse
of time, or both) under, or give rise to any right of termination, amendment, acceleration or cancellation of, any of the terms, conditions or provisions of any Contract to which such Stockholder is a party, or result in the creation of an
Encumbrance upon such Stockholder’s 

  
 3 

 
Subject Shares, other than in the case of clauses (B) and (C) as has not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect
on such Stockholder’s ability to perform its obligations under this Agreement. 
 (ii) Except for (A) compliance with any
applicable requirements of the Securities Act, the Exchange Act or any other United States state or federal securities Laws, (B) compliance with any NASDAQ rules, and (C) actions or filings the failure of which to be made or obtained has
not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on such Stockholder’s ability to perform its obligations under this Agreement, no consents or approvals of, or filings,
declarations or registrations with, any Governmental Authority or any other Person are necessary for the execution and delivery of this Agreement by such Stockholder and the consummation by such Stockholder of the transactions contemplated hereby.

 (d) Ownership of Subject Shares. As of the date hereof, such Stockholder (together with such Stockholder’s spouse if
such Stockholder is married and the Subject Shares constitute community property under applicable Law) is, and (except with respect to any Subject Shares Transferred (as defined below) in accordance with Section 3.2 hereof) at all times during
the Agreement Period will be, the record and beneficial owner of such Stockholder’s Subject Shares free and clear of any Encumbrances and with no restrictions on such Stockholder’s rights of voting or disposition pertaining thereto, except
for any applicable restrictions on Transfer under the Securities Act. Except to the extent of any Subject Shares acquired after the date hereof (which shall become Subject Shares upon that acquisition), the Subject Shares set forth on Schedule I
opposite the name of such Stockholder are the only shares of Company Common Stock beneficially owned by such Stockholder on the date hereof. Other than as set forth on Schedule I, such Stockholder does not beneficially own any (i) shares of
capital stock or other voting securities of or ownership interests in the Company, (ii) securities of the Company convertible into or exchangeable for shares of capital stock or other voting securities of or ownership interests in the Company,
or (iii) warrants, calls, options or other rights to acquire from the Company any capital stock or other voting securities or ownership interests in or any securities convertible into or exchangeable or exercisable for capital stock or other
voting securities or ownership interests in the Company. 
 (e) Proxy. Except for this Agreement, none of such
Stockholder’s Subject Shares are subject to any voting agreement, voting trust or other agreement or arrangement, including any proxy, consent or power of attorney, with respect to the voting of the Subject Shares on the date hereof, except
pursuant to this Agreement. Such Stockholder further represents that any proxies heretofore given in respect of the Subject Shares, if any, are revocable. 

(f) Absence of Litigation. With respect to such Stockholder, as of the date hereof, there is no Legal Proceeding pending or, to
the knowledge of such Stockholder, threatened against or affecting such Stockholder or any of his, her or its properties, assets or Affiliates (including such Stockholder’s Subject Shares) that could reasonably be expected to impair the ability
of such Stockholder to perform his, her or its obligations hereunder or to consummate the transactions contemplated hereby on a timely basis. 

  
 4 

 (g) Reliance. Such Stockholder understands and acknowledges that Parent and Merger
Sub are entering into the Merger Agreement in reliance upon such Stockholder’s execution, delivery and performance of this Agreement. 

(h) Finder’s Fees. No agent, broker, investment banker, finder or other intermediary is or will be entitled to any fee or
commission or reimbursement of expenses from Parent, or the Company or any of their respective Affiliates in respect of this Agreement based upon any arrangement or agreement made by or on behalf of such Stockholder. 

2.2 Representations and Warranties of Parent. Parent hereby represents and warrants to the Stockholders as follows: 

(a) Organization; Authorization. Parent (i) is a corporation duly organized, validly existing and in good standing under
the Laws of Delaware and (ii) has all requisite corporate power and authority necessary to own or lease and operate all of its properties and assets and to carry on its business as it is now being conducted. This Agreement has been duly
executed and delivered by Parent and constitutes a legal, valid and binding obligation of Parent and, assuming the due authorization, execution and delivery hereof by the Stockholders, is enforceable against Parent in accordance with their
respective terms, subject in each case to the Bankruptcy and Equity Exception. 
 (b) No Conflict. 

(i) Neither the execution and delivery of this Agreement by Parent nor the consummation by Parent of the transactions contemplated
hereby, nor compliance by Parent with any of the terms or provisions hereof, will (A) conflict with or violate any provision of the certificate of incorporation and bylaws of Parent, in each case as amended to the date of this Agreement,
(B) assuming that each of the filings referred to in Section 2.2(b)(ii) are made and any applicable waiting periods referred to therein have expired, violate any Law or Judgment applicable to Parent or any of its Subsidiaries, or
(C) require any consent or other action by any Person under, result in any violation or breach of, result in the loss of a benefit under, conflict with any provision of, or constitute a default (with our without notice or lapse of time, or
both) under, or give rise to any right of termination, amendment, acceleration or cancellation of, any of the terms, conditions or provisions of any Contract to which Parent or any of its Subsidiaries is a party, other than in the case of clauses
(B) and (C) as has not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on such the ability of Parent to perform its obligations under this Agreement. 

(ii) Except for (A) compliance with any applicable requirements of the Securities Act, the Exchange Act or any other United
States state or federal securities Laws, (B) compliance with any New York Stock Exchange rules, and (C) actions or filings the failure of which to be made or obtained has not had, and would not reasonably be expected to have, individually
or in the aggregate, a material adverse effect on the ability of Parent to perform its obligations under this Agreement, no consents or approvals of, or filings, declarations or registrations with, any Governmental Authority or any other Person are
necessary for the execution and delivery of this Agreement by Parent and the consummation by Parent of the transactions contemplated hereby. 

  
 5 

 SECTION 3 CERTAIN COVENANTS 

3.1 No Solicitation. Without limiting and subject to the provisions of Section 4.15 hereof, during the Agreement Period, each
Stockholder (solely in his, her or its capacity as a stockholder of the Company) agrees that it will not, directly or indirectly, take any action or omit to take any action that the Company is not permitted to take or omit to take pursuant to
Section 5.3 of the Merger Agreement. 
 3.2 No Proxies for or Encumbrances on Subject Shares.  

(a) Except pursuant to the terms of this Agreement, including Section 3.2(b), during the Agreement Period, no Stockholder shall
(nor permit any Person under such Stockholder’s control to), without the prior written consent of Parent, directly or indirectly, (i) grant any proxies, consents, powers of attorney, rights of first offer or refusal or enter into any
voting trust or voting agreement or arrangement with respect to the voting of any Subject Shares, (ii) sell (including short sell), assign, transfer, tender, pledge, encumber, grant a participation interest in, hypothecate, place in trust or
otherwise dispose of (including by gift), whether voluntarily or by operation of Law, or limit its right, title or interest or right to vote in any manner with respect to (except, in each case, by will or under the laws of intestacy) any Subject
Shares (each, a “Transfer”), (iii) enter into any Contract with respect to the direct or indirect Transfer of any Subject Shares, or (iv) otherwise permit any Encumbrances to be created on any Subject Shares. Each
Stockholder shall not, and shall not permit any Person under such Stockholder’s control to, and shall direct and use its reasonable best efforts to cause its and their respective Representatives to, seek or solicit any such Transfer or any such
Contract, and each Stockholder agrees promptly to notify Parent, and to provide all details requested by Parent, if such Stockholder, any Person under such Stockholder’s control or any of its or their respective Representatives shall be
approached or solicited, directly or indirectly, by any Person with respect to any of the foregoing. For purposes of this Section 3.2(a), none of the Company or its Subsidiaries will be deemed to be a Representative of any Stockholder, and no
officer, director, employee, agent or advisor of the Company (in each case, solely in their capacities as such) will be deemed to be a Representative of any Stockholder. 

(b) Notwithstanding anything in Section 3.2(a) to the contrary, any Stockholder may Transfer Subject Shares (i) to any member
of such Stockholder’s immediate family (i.e., spouse, lineal descendant or antecedent, brother or sister, adopted child or grandchild or the spouse of any child, adopted child, grandchild or adopted grandchild), (ii) to a trust for
the sole benefit of such Stockholder or any member of such Stockholder’s immediate family, (iii) upon the death of such Stockholder, (iv) in the case of a Stockholder that is an entity, to any parent entity, subsidiary or affiliate
under common control with such Stockholder, or to a partner or member of such Stockholder, or (v) to effect a cashless exercise for the primary purpose of paying the exercise price of Options or to cover tax withholding obligations in
connection with such exercise to the extent permitted by the instruments representing such Options; provided, that a Transfer referred to in clause (i) through (iv) of this Section 3.2(b) shall be permitted only if the
transferee agrees in writing to be bound by the terms of this Agreement. 
 3.3 Documentation and Information. Each Stockholder
(a) consents to and authorizes the publication and disclosure by Parent of such Stockholder’s identity and holding of 

  
 6 

 
Subject Shares, the nature of such Stockholder’s commitments, arrangements and understandings under this Agreement (including, for clarity, the disclosure of this Agreement) and any other
information, in each case, that Parent reasonably determines is required to be disclosed by applicable Law in any press release, any schedules and documents filed with the SEC or any other disclosure document in connection with the Transactions, and
(b) agrees promptly to give to Parent any information related to such Stockholder it may reasonably require for the preparation of any such disclosure documents. Each Stockholder agrees promptly to notify Parent of any required corrections with
respect to any information supplied by such Stockholder specifically for use in any such disclosure document, if and to the extent that any such information shall have become false or misleading in any material respect. Parent hereby consents to and
authorizes each Stockholder to make such disclosure or filings to the extent required by the SEC or NASDAQ. 
 3.4 Additional Subject
Shares. In the event that a Stockholder acquires record or beneficial ownership of, or the power to vote or direct the voting of, any additional voting interest with respect to the Company, such voting interests shall, without further action of
the parties, be subject to the provisions of this Agreement, and the number of Subject Shares set forth on Schedule I opposite the name of such Stockholder will be deemed amended accordingly. Each Stockholder shall promptly notify Parent of any such
event. 
 3.5 Certain Adjustments. In the event of a stock split, stock dividend or distribution, or any change in the shares
of Company Common Stock by reason of a stock split, reverse stock split, recapitalization, combination, reclassification, readjustment, exchange of shares or the like, the term “Subject Shares” shall be deemed to refer to and include such
shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged. 

3.6 Waiver of Appraisal Rights and Actions. Each Stockholder hereby (a) irrevocably waives and agrees not to exercise any and all
rights such Stockholder may have as to appraisal or dissent with respect to any of such Stockholder’s Subject Shares that may arise with respect to the Merger or any of the Transactions, including under Section 262 of the DGCL, and
(b) agrees (i) not to commence or participate in, and (ii) to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any
of their respective successors relating to the negotiation, execution or delivery of this Agreement or the Merger Agreement or the consummation of the Merger, including any such claim (A) challenging the validity of, or seeking to enjoin the
operation of, any provision of this Agreement, or (B) alleging a breach of any fiduciary duty of the Company Board in connection with the Merger Agreement or the Transactions. 

3.7 Notices of Certain Events. Each Stockholder shall notify Parent of any development occurring after the date hereof that causes, or
that would reasonably be expected to cause, any breach of any of the representations and warranties of such Stockholder set forth in Section 2.1. 

3.8 Further Assurances. Parent and each Stockholder will each execute and deliver, or cause to be executed and delivered, all further
documents and instruments and use their  

  
 7 

 
respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper or advisable under applicable Laws, in order
to perform their respective obligations under this Agreement. 
 SECTION 4 MISCELLANEOUS 

4.1 Notices. All notices, requests and other communications to any party hereunder shall be in writing and shall be deemed given if
delivered personally, facsimiled (which is confirmed) or sent by overnight courier (providing proof of delivery) to the parties at the following addresses:  
  

			
	if to Parent, to:
	
	Forest Laboratories, Inc.
	909 Third Avenue
	New York, NY 10022
	Attention:	  	A. Robert D. Bailey, General Counsel
	Facsimile:	  	(212) 224-6740
	
	with a copy (which shall not constitute notice) to:
	
	 Covington & Burling LLP

The New York Times Building
 620 Eighth Avenue

	New York, NY 10018
	Attention:	  	Andrew W. Ment
	Facsimile:	  	(646) 441-9012
	
	if to a Stockholder, to his, her or its address set forth on a signature page hereto, with a copy (which shall not constitute notice) to each of:
	
	Kirkland & Ellis LLP
	601 Lexington Avenue
	New York, New York 10022
	Attention:	  	Stephen Fraidin
		  	Richard Brand
	Facsimile:	  	(212) 446-6460
		
	and	  	
	
	 Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300
 Raleigh, North Carolina
27607

	Attention:	  	Donald R. Reynolds
		  	Amy E. Risseeuw
	Facsimile:	  	(919) 781-4865

  
 8 

 4.2 Amendment; Waiver. Any provision of this Agreement may be amended or waived during the
Agreement Period if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be effective. No failure or
delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or
privilege. 
 4.3 Termination. This Agreement shall automatically terminate and become void and of no further force or effect
on the earlier of (i) the Effective Time, (ii) with respect to each Stockholder, the termination of this Agreement by written notice from such Stockholder to Parent following the amendment, modification or waiver of the terms of the Merger
Agreement to (y) reduce or change the form of the consideration to be paid to such Stockholder in connection with the Merger or (z) create any additional conditions to the consummation of the Merger, (iii) the termination of this
Agreement by written notice from Parent to the Stockholders, and (iv) the termination of the Merger Agreement in accordance with its terms (the period from the date hereof through such time being referred to as the “Agreement
Period”); provided that (x) Section 4.1, Section 4.2, Section 4.5, Section 4.9, Section 4.10 and Section 4.15 shall survive such termination, and (y) upon termination of this Agreement, all
obligations of the parties hereunder will terminate, without any liability or other obligation on the part of any party hereto to any Person in respect hereof or the transactions contemplated hereby, and no party shall have any claim against another
(and no person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the subject matter hereof; provided that the termination of this Agreement shall not relieve any party from liability arising
from fraud or any willful and intentional breach prior to such termination. For clarity, this Agreement shall not terminate upon a Company Adverse Recommendation Change unless the Merger Agreement is terminated. 

4.4 No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in Parent any direct or indirect ownership or
incidence of ownership of or with respect to any Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares shall remain vested in and belong to the Stockholders, and Parent shall have no authority to direct
any Stockholder in the voting or disposition of any of the Subject Shares, except as otherwise provided herein. 
 4.5
Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs or expenses, whether or not the Transactions are consummated. 

4.6 Representations and Warranties. The representations and warranties contained in this Agreement and in any certificate or other
writing delivered pursuant hereto shall not survive the Effective Time or the termination of this Agreement. 
 4.7 Entire
Agreement; Counterparts. This Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof and
thereof. This Agreement may be executed in counterparts (each of which shall be deemed to be an original but  

  
 9 

 
all of which taken together shall constitute one and the same agreement) and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by
electronic communication, facsimile or otherwise) to the other parties. Until and unless each party has received a counterpart hereof signed by the other parties hereto, this Agreement shall have no effect and no party shall have any right or
obligation hereunder (whether by virtue of any other oral or written agreement or other communication). 
 4.8 Assignment; Third Party
Beneficiaries. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors and assigns. No party may assign, delegate or otherwise transfer any of its rights or obligations
under this Agreement without the consent of each other party; provided that the reorganization, consolidation or change of control of Parent shall not be considered an assignment for purposes hereof. This Agreement is not intended to and
shall not confer upon any Person other than the parties hereto (and their respective heirs, successors and permitted assigns) any rights, remedies, benefits, obligations, liabilities or claims hereunder. No assignment by any party shall relieve such
party of any of its obligations hereunder.  
 4.9 Governing Law; Jurisdiction.  

(a) This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to
any choice or conflict of laws provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. 

(b) Each of the parties hereto hereby agrees that (i) all actions and proceedings arising out of or relating to this Agreement
shall be heard and determined in the Chancery Court of the State of Delaware and any state appellate court therefrom sitting in New Castle County in the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept
jurisdiction over a particular matter, any state or federal court within the State of Delaware), (ii) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, and
(iii) a final Judgment in any action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the Judgment or in any other manner provided by Law. 

(c) Each party irrevocably consents to the service of process outside the territorial jurisdiction of the courts referred to in this
Section 6.6 in any such action or proceeding by mailing copies thereof by registered or certified United States mail, postage prepaid, return receipt requested, to its address as specified in or pursuant to this Agreement. However, the
foregoing shall not limit the right of a party to effect service of process on the other party by any other legally available method. 

4.10 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
BETWEEN THE PARTIES HERETO ARISING OUT OF OR RELATING TO THIS AGREEMENT. 

  
 10 

 4.11 Severability. If any term or other provision of this Agreement is determined by a
court of competent jurisdiction or other Governmental Authority to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms, provisions and conditions of this Agreement shall nevertheless remain in full
force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible to the fullest extent permitted by applicable law in a mutually acceptable manner to the end that the transactions contemplated by this Agreement are fulfilled to the extent possible. 

4.12 Enforcement. The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms
and provisions of this Agreement in any federal court located in the State of Delaware or any Delaware state court, this being in addition to any other remedy to which they are entitled at law or in equity. 

4.13 Construction. When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement
unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” or
“including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and “hereunder” and words of similar import when used in
this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine
as well as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement, instrument or statute as from time to
time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of comparable successor statutes and references to all attachments thereto and instruments
incorporated therein and the rules and regulations promulgated thereunder. References to a Person are also to its permitted assigns and successors. 

4.14 No Presumption. Each of the parties agrees that he, she or it has had the opportunity to review this Agreement with counsel of
his, her or its own choosing and, therefore, waives the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or
document. 

  
 11 

 4.15 Obligations; Stockholder Capacity. The obligations of each Stockholder under this
Agreement are several and not joint, and no Stockholder shall have any liability or obligation under this Agreement for any breach hereunder by any other Stockholder. Each Stockholder is signing and entering this Agreement solely in his, her or its
capacity as the beneficial owner of such Stockholder’s Subject Shares, and nothing herein shall limit or affect in any way any actions that may be hereafter taken by him, her or it in his, her or its capacity as an employee, officer or director
of the Company or any of its Subsidiaries, and no such action or omission shall constitute a breach of this Agreement. 

[Signature Page Follows] 

  
 12 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by its duly authorized officers as of the day and year first above written. 
  

					
	FOREST LABORATORIES, INC.
		
	By:	 	 /S/ A. ROBERT D. BAILEY

		 	Name:	 	A. Robert D. Bailey
		 	Title:	 	Senior Vice President, Chief Legal Officer and General Counsel

 SIGNATURE PAGE 

STOCKHOLDER VOTING AGREEMENT 

 
			
	FRED N. ESHELMAN
	
	 /S/ FRED N. ESHELMAN

	Name:	 	Fred N. Eshelman
	Address:	 	
		
	Attention:	 	
	Facsimile:	 	
	
	 WALKER TAYLOR IV, TRUSTEE OF THE FREDRIC N. ESHELMAN 2009

GRANTOR RETAINED ANNUITY TRUST
 IRREVOCABLE TRUST
AGREEMENT DATED 8/21/2009

	
	 /S/ WALKER TAYLOR IV

	Name:	 	Walker Taylor IV
	Address:	 	
		
	Attention:	 	
	Facsimile:	 	
	
	ELK MOUNTAIN CONSULTING, LLC
	
	 /S/ FRED N. ESHELMAN

	Name:	 	Fred N. Eshelman
	Address:	 	
		
	Attention:	 	
	Facsimile:	 	
	
	APRIL ESHELMAN
	
	 /S/ APRIL ESHELMAN

	Name:	 	April Eshelman
	Address:	 	
		
	Attention:	 	
	Facsimile:	 	

 SIGNATURE PAGE 

STOCKHOLDER VOTING AGREEMENT 

 SCHEDULE I 

SUBJECT SHARES 
  

					
	 Stockholder
	  	Total Number of Subject
Shares	 
	 Fredric N. Eshelman
	  	 	2,673,522	(1) 
	 Walker Taylor IV, Trustee of the Fredric N. Eshelman 2009 Grantor Retained Annuity Trust Irrevocable Trust Agreement Dated
8/21/2009
	  	 	41,666	  
	 Elk Mountain Consulting, LLC
	  	 	264,440	(2) 
	 April Eshelman
	  	 	140	  

  

	(1)	Includes 7,161 shares of restricted stock that are scheduled to vest within 60 days of the date of this Agreement. 

	(2)	Includes 131,751 shares issuable upon exercise of options.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]